WH1fungin a surfactin cyclic lipopeptide is a novel oral immunoadjuvant

Vaccine

Volumn 31, Issue 26, 2013, Pages 2796-2803

  Gao, Zhenqiu ^a,b   Zhao, Xiuyun ^a   Lee, Song ^c   Li, Jingjing ^a   Liao, Hao ^a   Zhou, Xiaohui ^d   Wu, Jie ^b   Qi, Gaofu ^a  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c DALHOUSIE UNIVERSITY   (Canada)

^d FUDAN UNIVERSITY   (China)

Author keywords

Oral adjuvant; Surfactin; Vaccine; WH1fungin

Indexed keywords

CHOLERA TOXIN B SUBUNIT; GAMMA INTERFERON; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; LIPOPEPTIDE; OVALBUMIN; PEPSIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WH1 FUNGIN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG POTENTIATION; GASTROINTESTINAL TRACT; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PH; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; STOMACH JUICE; TH1 TH2 BALANCE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODY FORMATION; ANTIGENS; CELL LINE; GLUTATHIONE TRANSFERASE; IMMUNITY, MUCOSAL; INTESTINES; LIPOPEPTIDES; MALE; MICE; MICE, INBRED C57BL; OVALBUMIN; PEPTIDES, CYCLIC; T-LYMPHOCYTES;

EID: 84878423643     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.028     Document Type: Article

References (31)

1. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
2. Salman H.H., Irache J.M., Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 2009, 27:4784-4790.
3. Slütter B., Plapied L., Fievez V., Sande M.A., Des Rieux A., Schneider Y.J., et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 2009, 138:113-121.
4. Dubois B., Goubier A., Joubert G., Kaiserlian D. Oral tolerance and regulation of mucosal immunity. Cell Mol Life Sci 2005, 62:1322-1332.
5. Mowat A.M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003, 3:331-341.
6. Lawson L.B., Norton E.B., Clements J.D. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011, 23:414-420.
7. Freytag L.C., Clements J.D. Mucosal adjuvants. Vaccine 2005, 23:1804-1813.
8. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350:896-903.
9. Van Ginkel F.W., Jackson R.J., Yoshino N., Hagiwara Y., Metzger D.J., Connell T.D., et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 2005, 73:6892-6902.
10. Schwarz T. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine. Cervarix Adv Ther 2009, 26:983-998.
11. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
12. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004, 4:249-259.
13. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82:488-496.
14. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010, 9(9):1095-1107.
15. Shaligram N.S., Singhal R.S. Surfactin - a review on biosynthesis, fermentation, purification and applications. Food Technol Biotechnol 2010, 48:119-134.
16. Qi G., Zhu F., Du P., Yang X., Qiu D., Yu Z., et al. Lipopeptide induces apoptosis in fungal cells by a mitochondria-dependent pathway. Peptides 2010, 31:1978-1986.
17. Gao Z., Wang S., Qi G., Pan H., Zhang L., Zhou X., et al. A surfactin cyclopeptide of WH1fungin used as a novel adjuvant for intramuscular and subcutaneous immunization in mice. Peptides 2012, 38:163-171.
18. Seydlová G., Svobodová J. Review of surfactin chemical properties and the potential biomedical applications. Cent Eur J Med 2008, 3:123-133.
19. Knoblich A., Matsumoto M., Ishiguro R., Murata K., Fujiyoshi Y., Ishigami Y., et al. Electron cryo-microscopic studies on micellar shape and size of surfactin, an anionic lipopeptide. Colloid Surface B: Biointerfaces 1995, 5:43-48.
20. Straus S.K., Hancock R.E.W. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 2006, 1758:1215-1223.
21. + T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors. Cancer Sci 2008, 99:1008-1015.
22. Cho J.Y., Baik K.U., Yoo E.S., Yoshikawa K., Park M.H. In Vitro anti-inflammatory effects of neolignan woorenosides from the rhizomes of Coptis japonic. J Nat Prod 2000, 63:1205-1209.
23. Zhou X., Kong N., Wang J., Fan H., Zou H., Horwitz D., et al. All-Trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J Immunol 2010, 185:2675-2679.
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
25. Sloat B.R., Sandoval M.A., Hau A.M., He Y., Cui Z. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J Control Release 2010, 141:93-100.
26. Hirabayashi Y., Kurata H., Funato H., Nagamine T., Aizawa C., Tamura S., et al. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 1990, 8:243-248.
27. Weltzin R., Guy B., Thomas W.D., Giannasca P.J., Monath T.P. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun 2000, 68:2775-2782.
28. De Becker G., Moulin V., Pajak B., Bruck C., Francotte M., Thiriart C., et al. The adjuvant monophos-phoryl lipid A increases the function of Ag-presenting cells. Int Immunol 2000, 12:807-815.
29. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
30. Datta S.K., Sabet M., Nguyen K.P.L., Valdez P.A., Gonzalez-Navajas J.M., Islam S., et al. Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci USA 2010, 107:10638-10643.
31. Lee S.F., Halperin S.A., Salloum D.F., MacMillan A., Morris A. Mucosal immunization with a genetically engineered Pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. Infect Immun 2003, 71:2272-2275.